ANDA 219134, held by Teva Pharms Inc. Nilotinib Hydrochloride.
As of Nov 16, 2026, ANDA 219134 (Nilotinib Hydrochloride), held by Teva Pharms Inc, was first approved by FDA on Jun 26, 2026, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 26, 2026 | Original application | Approved | None posted |
| Nilotinib HydrochlorideEQ 50MG BASE · capsule;oral | Nilotinib Hydrochloride | Rx |
| Nilotinib HydrochlorideEQ 150MG BASE · capsule;oral | Nilotinib Hydrochloride | Rx |
| Nilotinib HydrochlorideEQ 200MG BASE · capsule;oral | Nilotinib Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters